OBJECTIVE: To describe the clinical features of Creutzfeldt-Jakob disease with a substitution of arginine for methionine (M232R substitution) at codon 232 (CJD232) of the prion protein gene (PRNP). PATIENTS AND METHODS: We evaluated the clinical and laboratory features of 20 CJD232 patients: age of onset, initial symptoms, duration until becoming akinetic and mute, duration until occurrence of periodic sharp and wave complexes on EEG (PSWC), MRI findings, and the presence of CSF 14-3-3 protein. Immunohistochemically, prion protein (PrP) deposition was studied. RESULTS: None of the patients had a family history of CJD. We recognized two clinical phenotypes: a rapidly progressive type (rapidtype) and a slowly progressive type (slow-type). Out of 20 patients, 15 became akinetic and mute, demonstrated myoclonus, and showed PSWC within a mean duration of 3.1, 2.4, and 2.8 months, respectively (rapid-type). Five showed slowly progressive clinical courses (slow-type). Five became akinetic and mute and four demonstrated myoclonus within a mean duration of 20.6 and 15.3 months, respectively, which were significantly longer than those in the rapid-type. Only one demonstrated PSWC 13 months after the onset. Diffuse synaptic-type deposition was demonstrated in four rapidtype patients, and perivacuolar and diffuse synaptic-type deposition in two, and diffuse synaptic-type deposition in one slow-type patient. Three of 50 suspected but non-CJD patients had the M232R substitution. CONCLUSIONS: Patients with CJD232 had no family history like patients with sCJD, and showed two different clinical phenotypes in spite of having the same PRNP genotype. More studies are needed to determine whether M232R substitution causes the disease and influences the disease progression.
OBJECTIVE: To describe the clinical features of Creutzfeldt-Jakob disease with a substitution of arginine for methionine (M232R substitution) at codon 232 (CJD232) of the prion protein gene (PRNP). PATIENTS AND METHODS: We evaluated the clinical and laboratory features of 20 CJD232 patients: age of onset, initial symptoms, duration until becoming akinetic and mute, duration until occurrence of periodic sharp and wave complexes on EEG (PSWC), MRI findings, and the presence of CSF 14-3-3 protein. Immunohistochemically, prion protein (PrP) deposition was studied. RESULTS: None of the patients had a family history of CJD. We recognized two clinical phenotypes: a rapidly progressive type (rapidtype) and a slowly progressive type (slow-type). Out of 20 patients, 15 became akinetic and mute, demonstrated myoclonus, and showed PSWC within a mean duration of 3.1, 2.4, and 2.8 months, respectively (rapid-type). Five showed slowly progressive clinical courses (slow-type). Five became akinetic and mute and four demonstrated myoclonus within a mean duration of 20.6 and 15.3 months, respectively, which were significantly longer than those in the rapid-type. Only one demonstrated PSWC 13 months after the onset. Diffuse synaptic-type deposition was demonstrated in four rapidtype patients, and perivacuolar and diffuse synaptic-type deposition in two, and diffuse synaptic-type deposition in one slow-type patient. Three of 50 suspected but non-CJD patients had the M232R substitution. CONCLUSIONS: Patients with CJD232 had no family history like patients with sCJD, and showed two different clinical phenotypes in spite of having the same PRNP genotype. More studies are needed to determine whether M232R substitution causes the disease and influences the disease progression.
Authors: Gábor G Kovács; Gianriccardo Trabattoni; Johannes A Hainfellner; James W Ironside; Richard S G Knight; Herbert Budka Journal: J Neurol Date: 2002-11 Impact factor: 4.849
Authors: M Yamada; Y Itoh; A Inaba; Y Wada; M Takashima; S Satoh; T Kamata; R Okeda; T Kayano; N Suematsu; T Kitamoto; E Otomo; M Matsushita; H Mizusawa Journal: Neurology Date: 1999-07-13 Impact factor: 9.910
Authors: Ana Lia Taratuto; P Piccardo; E G Reich; S G Chen; G Sevlever; M Schultz; A A Luzzi; M Rugiero; G Abecasis; M Endelman; A M Garcia; S Capellari; Z Xie; E Lugaresi; P Gambetti; S R Dlouhy; B Ghetti Journal: Neurology Date: 2002-02-12 Impact factor: 9.910
Authors: Andrew F Hill; Susan Joiner; Jonathan D F Wadsworth; Katie C L Sidle; Jeanne E Bell; Herbert Budka; James W Ironside; John Collinge Journal: Brain Date: 2003-06 Impact factor: 13.501
Authors: K Jin; Y Shiga; S Shibuya; K Chida; Y Sato; H Konno; K Doh-ura; T Kitamoto; Y Itoyama Journal: Neurology Date: 2004-02-10 Impact factor: 9.910
Authors: M Pocchiari; M Puopolo; E A Croes; H Budka; E Gelpi; S Collins; V Lewis; T Sutcliffe; A Guilivi; N Delasnerie-Laupretre; J-P Brandel; A Alperovitch; I Zerr; S Poser; H A Kretzschmar; A Ladogana; I Rietvald; E Mitrova; P Martinez-Martin; J de Pedro-Cuesta; M Glatzel; A Aguzzi; S Cooper; J Mackenzie; C M van Duijn; R G Will Journal: Brain Date: 2004-09-10 Impact factor: 13.501
Authors: Mee-Ohk Kim; Leonel T Takada; Katherine Wong; Sven A Forner; Michael D Geschwind Journal: Cold Spring Harb Perspect Biol Date: 2018-05-01 Impact factor: 10.005
Authors: Joel C Watts; Kurt Giles; Ana Serban; Smita Patel; Abby Oehler; Sumita Bhardwaj; Shenheng Guan; Michael D Greicius; Bruce L Miller; Stephen J DeArmond; Michael D Geschwind; Stanley B Prusiner Journal: Ann Neurol Date: 2015-08-25 Impact factor: 10.422
Authors: Leonel T Takada; Mee-Ohk Kim; Ross W Cleveland; Katherine Wong; Sven A Forner; Ignacio Illán Gala; Jamie C Fong; Michael D Geschwind Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2017-01 Impact factor: 3.568
Authors: Michael P Heaton; Kreg A Leymaster; Theodore S Kalbfleisch; Brad A Freking; Timothy P L Smith; Michael L Clawson; William W Laegreid Journal: BMC Vet Res Date: 2010-04-30 Impact factor: 2.741
Authors: Sol Moe Lee; Young Ran Ju; Bo-Yeong Choi; Jae Wook Hyeon; Jun Sun Park; Chi Kyeong Kim; Su Yeon Kim Journal: Prion Date: 2012-05-07 Impact factor: 3.931